• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Appeals court nixes GSK’s petition for new trial in Vectura patent spat

November 20, 2020 By Nancy Crotti

The Federal Circuit Court has rejected Glaxo Smith Kline’s (NYSE:GSK) petition for a new trial in a patent case brought by British inhaler company Vectura.

The circuit court upheld a May 2019 jury verdict in U.S. District Court for the District of Delaware, awarding Ventura $89.7 million damages for the period from August 2016 through December 2018 for an infringement on Vectura’s U.S. patent 8303991 by sales of three of GSK’s Ellipta inhalers. The jury found that Vectura had proven that GlaxoSmithKline had infringed claim 3 of patent ‘991.

In September 2019, a federal judge in Delaware awarded Vectura:

  • An additional $10.5 million in compensatory damages.
  • Ongoing royalties of 3% on U.S. sales of certain infringing GSK Ellipta products.
  • Supplemental damages based on GSK’s infringing sales of approximately $10.5 million.
  • Pre-judgment interest at the prime rate of approximately $6.7 million.

GSK has 30 days to file a petition for rehearing. “We are disappointed with the ruling and are weighing our options,” a company spokesperson said in an email to Drug Delivery Business News.

Vectura filed the patent infringement lawsuit against GlaxoSmithKline in July 2016. The two companies entered an agreement in 2010 that stated that GlaxoSmithKline would take a license to make technology that was covered by Vectura’s patent family. The licensed patents expired in July 2016, at which point GlaxoSmithKline could license additional patent families under the original agreement. They declined the relicensing, resulting in Vectura’s lawsuit.

This article has been updated with a comment from GlaxoSmithKline.

Filed Under: Drug-Device Combinations, Featured, Legal News, Respiratory Tagged With: GlaxoSmithKline plc, Vectura

IN CASE YOU MISSED IT

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS